GSK-3 inhibition by an orally active small molecule increases bone mass in rats

Bone

Volumn 50, Issue 3, 2012, Pages 619-627

  Marsell, Richard ^a   Sisask, Gregor ^a   Nilsson, Yvonne ^b   Sundgren Andersson, Anna K ^b   Andersson, Ulf ^c   Larsson, Sune ^a   Nilsson, Olle ^a   Ljunggren, Östen ^a   Jonsson, Kenneth B ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Catenin; BMD; Bone formation; GSK 3; Osteoporosis; Wnt

Indexed keywords

AZD 2858; BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE MASS; CONTROLLED STUDY; DENSITOMETRY; DRUG BIOAVAILABILITY; DRUG POTENCY; FEMALE; HETEROZYGOSITY; IN VITRO STUDY; IN VIVO STUDY; LOADING TEST; MOLECULAR WEIGHT; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; TRABECULAR BONE;

ANIMALS; BETA CATENIN; BONE AND BONES; BONE DENSITY; BONE REMODELING; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; OSTEOBLASTS; RATS; RATS, SPRAGUE-DAWLEY; WNT SIGNALING PATHWAY;

EID: 84856968521     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.11.007     Document Type: Article

References (30)

1. Cummings S.R., Melton L.J. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002, 359(9319):1761-1767.
2. Boonen S., Laan R.F., Barton I.P., Watts N.B. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 2005, 16(10):1291-1298.
3. McCombs J.S., Thiebaud P., McLaughlin-Miley C., Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004, 48(3):271-287.
4. Guo R., Yamashita M., Zhang Q., Zhou Q., Chen D., Reynolds D.G., et al. Ubiquitin ligase Smurf1 mediates tumor necrosis factor-induced systemic bone loss by promoting proteasomal degradation of bone morphogenetic signaling proteins. J Biol Chem 2008, 283(34):23084-23092.
5. Guise T.A., Mohammad K.S., Clines G., Stebbins E.G., Wong D.H., Higgins L.S., et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006, 12(20 Pt 2):6213s-6216s.
6. Giuliani N., Rizzoli V., Roodman G.D. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006, 108(13):3992-3996.
7. Moon R.T. Wnt/ß-catenin pathway. Sci STKE 2005, 2005(271).
8. Little R.D., Carulli J.P., Del Mastro R.G., Dupuis J., Osborne M., Folz C., et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002, 70(1):11-19.
9. Kugimiya F., Kawaguchi H., Ohba S., Kawamura N., Hirata M., Chikuda H., et al. GSK-3beta controls osteogenesis through regulating Runx2 activity. PLoS One 2007, 2(9):e837.
10. Gong Y., Slee R.B., Fukai N., Rawadi G., Roman-Roman S., Reginato A.M., et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001, 107(4):513-523.
11. Van Wesenbeeck L., Cleiren E., Gram J., Beals R.K., Benichou O., Scopelliti D., et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 2003, 72(3):763-771.
12. Kato M., Patel M.S., Levasseur R., Lobov I., Chang B.H., Glass D.A., et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 2002, 157(2):303-314.
13. Holmen S.L., Giambernardi T.A., Zylstra C.R., Buckner-Berghuis B.D., Resau J.H., Hess J.F., et al. Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res 2004, 19(12):2033-2040.
14. Morvan F., Boulukos K., Clement-Lacroix P., Roman Roman S., Suc, Royer I., Vayssiere B., et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 2006, 21(6):934-945.
15. Babij P., Zhao W., Small C., Kharode Y., Yaworsky P.J., Bouxsein M.L., et al. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 2003, 18(6):960-974.
16. Wang F.S., Ko J.Y., Lin C.L., Wu H.L., Ke H.J., Tai P.J. Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats. Bone 2007, 40(2):485-492.
17. Grisanti M, Niu QT, Fan W, Asuncion F, Lee J, Steavenson S, et al. Dkk-1 Inhibition Increases Bone Mineral Density in Rodents. ASBMR Annual Meeting, Philadelphia, USA 2006, Oral Presentation 1089.
18. Li X., Ominsky M.S., Warmington K.S., Morony S., Gong J., Cao J., et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009 Apr, 24(4):578-588.
19. Gordon M.D., Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 2006, 281(32):22429-22433.
20. Mussmann R., Geese M., Harder F., Kegel S., Andag U., Lomow A., et al. Inhibition of GSK3 promotes replication and survival of pancreatic beta cells. J Biol Chem 2007, 282(16):12030-12037.
21. Jope R.S., Yuskaitis C.J., Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 2007, 32(4-5):577-595.
22. Bhat R.V., Budd Haeberlein S.L., Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 2004, 89(6):1313-1317.
23. Clement-Lacroix P., Ai M., Morvan F., Roman-Roman S., Vayssiere B., Belleville C., et al. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci U S A 2005, 102(48):17406-17411.
24. Kulkarni N.H., Onyia J.E., Zeng Q., Tian X., Liu M., Halladay D.L., et al. Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res 2006, 21(6):910-920.
25. Nakamura K., Tanaka T., Kuwahara A., Takeo K. Microassay for proteins on nitrocellulose filter using protein dye-staining procedure. Anal Biochem 1985, 148(2):311-319.
26. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987, 2(6):595-610.
27. Vestergaard P., Jorgensen N.R., Mosekilde L., Schwarz P. Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk-a meta-analysis. Osteoporos Int 2007, 18(1):45-57.
28. Day T.F., Guo X., Garrett-Beal L., Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 2005, 8(5):739-750.
29. Hill T.P., Später D., Taketo M.M., Birchmeier W., Hartmann C. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 2005, 8(5):727-738.
30. Glass D.A., Bialek P., Ahn J.D., Starbuck M., Patel M.S., Clevers H., et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005, 8(5):751-764.